Clinical Trials Directory

Trials / Terminated

TerminatedNCT00233558

Open-Label Steroid Reduction Study of Adalimumab With Methotrexate in Patients With Active Rheumatoid Arthritis

Multicentre, Randomised, Open Label Study Comparing a "Scheduled Steroid Reduction Strategy" Versus a Free Steroid Reduction Strategy (Physician's Usual Practice for Reducing Steroids) in Patients With Active RA Treated With Humira 40 mg Eow + MTX During 9 Months

Status
Terminated
Phase
Phase 4
Study type
Interventional
Enrollment
160 (planned)
Sponsor
Abbott · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of the study is to evaluate the clinical efficacy of scheduled versus free reduction of steroid treatment in patients with active RA treated with adalimumab + MTX

Conditions

Interventions

TypeNameDescription
DRUGadalimumab (up to 9 months exposure)
DRUGmethotrexate

Timeline

Start date
2005-06-01
First posted
2005-10-06
Last updated
2007-04-24

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00233558. Inclusion in this directory is not an endorsement.

Open-Label Steroid Reduction Study of Adalimumab With Methotrexate in Patients With Active Rheumatoid Arthritis (NCT00233558) · Clinical Trials Directory